Combination of virtual screening and high throughput gene profiling for identification of novel liver X receptor modulators.

We conducted virtual docking studies using GLIDE with modified LXRbeta ligand-binding domain (LBD) on internal compound collection followed by the gene profiling with ArrayPlate mRNA assay. A total of 69 compounds were found to upregulate LXRalpha and certain LXR regulated genes from 1308 compounds selected by virtual screen (hit rate: 5.3%). Compound 4 was shown to significantly induce the expression of LXR target genes such as ABCA1, ABCG1, APOE, SCD-1, and SREBP-1c in THP-1 differentiated macrophages. In vitro binding assay confirmed that 4 binds to both LXRalpha and LXRbeta directly and recruits coactivator peptide SRC-1. It functions as a full LXR agonist in stimulating cholesterol efflux in THP-1 differentiated macrophages and induces lipogenesis in HepG2 cells. This study demonstrates that the combination of virtual screen and high throughput gene profiling is an efficient approach for rapid identification of novel LXR modulators.

[1]  Christopher Miller,et al.  Discovery of phenyl acetic acid substituted quinolines as novel liver X receptor agonists for the treatment of atherosclerosis. , 2006, Journal of medicinal chemistry.

[2]  Gennady M Verkhivker,et al.  Molecular recognition of the inhibitor AG-1343 by HIV-1 protease: conformationally flexible docking by evolutionary programming. , 1995, Chemistry & biology.

[3]  E. Moir,et al.  Liver X receptor agonists as a treatment for atherosclerosis , 2004 .

[4]  James D. Johnson,et al.  β-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment , 2007, Nature Medicine.

[5]  J. Medina,et al.  Discovery and optimization of a novel series of liver X receptor-α agonists , 2006 .

[6]  Timothy M. Willson,et al.  Activation of the Nuclear Receptor LXR by Oxysterols Defines a New Hormone Response Pathway* , 1997, The Journal of Biological Chemistry.

[7]  H. Nar,et al.  Crystal structure of the human liver X receptor beta ligand-binding domain in complex with a synthetic agonist. , 2004, Journal of molecular biology.

[8]  J. Menke,et al.  Liver X receptor agonists as potential therapeutic agents for dyslipidemia and atherosclerosis. , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[9]  P. Tontonoz,et al.  LXR: A nuclear receptor target for cardiovascular disease? , 2005 .

[10]  L. Moore,et al.  Williams, S. et al. X-ray crystal structure of the liver X receptor ligand binding domain: regulation by a histidine-tryptophan switch. J. Biol. Chem. 278, 27138-27143 , 2003 .

[11]  Gerhard Klebe,et al.  Comparison of Automatic Three-Dimensional Model Builders Using 639 X-ray Structures , 1994, J. Chem. Inf. Comput. Sci..

[12]  John E. Williams,et al.  An open pilot study investigating the use of a strong sublingual opioid (phenazocine) for postoperative analgesia , 2000 .

[13]  D. A. Morales,et al.  Multiplexed screening assay for mRNA combining nuclease protection with luminescent array detection. , 2002, Assay and drug development technologies.

[14]  Sherry Sun,et al.  The Three-dimensional Structure of the Liver X Receptor β Reveals a Flexible Ligand-binding Pocket That Can Accommodate Fundamentally Different Ligands* , 2003, Journal of Biological Chemistry.

[15]  Timothy M Willson,et al.  Identification of a nonsteroidal liver X receptor agonist through parallel array synthesis of tertiary amines. , 2002, Journal of medicinal chemistry.

[16]  M. Jaye.  LXR agonists for the treatment of atherosclerosis. , 2003, Current opinion in investigational drugs.

[17]  Eric Westhof,et al.  Halogen bonds in biological molecules. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[18]  Abby L. Parrill,et al.  Rational drug design : novel methodology and practical applications , 1999 .

[19]  T. Willson,et al.  Synthetic LXR ligand inhibits the development of atherosclerosis in mice , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[20]  Angela Smallwood,et al.  Discovery of substituted maleimides as liver X receptor agonists and determination of a ligand-bound crystal structure. , 2005, Journal of medicinal chemistry.

[21]  D. Mangelsdorf,et al.  Role of LXRs in control of lipogenesis. , 2000, Genes & development.

[22]  N. Mitro,et al.  The nuclear receptor LXR is a glucose sensor , 2007, Nature.

[23]  Y. Morikawa,et al.  T‐0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptor‐deficient mice , 2003, FEBS letters.